Toward increased sensitivity and specificity in the treatment of neoplastic diseases

Journal of the American Dental Association

Volumn 129, Issue 4, 1998, Pages 473-478

  Slavkin, Harold C ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; INTEGRIN; PEPTIDE FRAGMENT; PLASMINOGEN;

ARTICLE; DRUG DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; VASCULARIZATION;

ANGIOSTATINS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTEGRINS; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY;

EID: 0032040176     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.1998.0247     Document Type: Article

References (6)

1. National Cancer Institute. Surveillance, Epidemiology, and End Result (SEER) database. January 1997.
2. American Cancer Society. Cancer facts and figures - 1997. Atlanta: American Cancer Society; 1997.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996:86:353-64.
4. Bochm T, Folkman J, Browder T, O'Reilly M. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
5. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
6. Brooks PC, Silletti S, von Schalscha L, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.